The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Related Articles
CHMP Recommends Liso-cel in Pretreated R/R Follicular Lymphoma for Approval
The TRANSCEND FL trial showed that liso-cel elicited an ORR of 97.1% and a complete response rate of 94.2% in patients with follicular lymphoma.
FDA Accepts BLA for Pertuzumab Biosimilar in HER2+ Breast Cancer
The FDA accepted a BLA seeking the approval of the pertuzumab biosimilar HLX11 for HER2-positive breast cancer.
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Home | AML Hub
Online resource for healthcare professionals, providing information, news & support relating to AML
🚨 The OncoAlert Colloquium Feb 2025
A 100% virtual, week-long meeting highlighting the most important developments in oncology each year, delivered by some of the world’s leading oncologists in a multidisciplinary…
Encorafenib/Cetuximab Plus Chemo Improves Survival in BRAF V600E+ mCRC
Encorafenib plus cetuximab and mFOLFOX6 improved PFS and OS vs chemotherapy in BRAF V600E–mutant metastatic colorectal cancer.
NSCLC Experts Ponder Best First-Line Treatment Options
The discussion on NSCLC narrowed in on findings from recent clinical trials, particularly involving a combination regimen of amivantamab plus lazertinib vs osimertinib and chemotherapy.
Managing Unseen Risks: Understanding Recurrence in Early Breast Cancer With No or Limited Nodal Involvement
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
TACE and Durvalumab/Bevacizumab in Unresectable HCC
“Durvalumab plus bevacizumab plus [transarterial chemoembolization (TACE)] has the potential to set a new standard of care” in this patient population, according to researchers who…
